Cowen and Company’s Vor Biopharma VOR Stock Holding History

Cowen and Company’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-61,030	Closed	-$854K	–	307
2024 Q3	$854K	Buy	+61,030	New	+$1.11M	0.03%	163

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cowen and Company's VOR Position: Q4 2024 in Review

Cowen and Company sold out of Vor Biopharma (VOR) in Q4 2024, closing a stake of 61,030 shares — an estimated $854K sold.

Cowen and Company first reported a position in VOR in Q3 2024 and held it in 1 quarter. The position peaked at $854K in Q3 2024. 50 funds tracked by Wall St. Rank hold VOR as of Q4 2024.

Cowen and Company reported no remaining Vor Biopharma position as of Q4 2024 after selling out during the quarter.
Cowen and Company sold 61,030 Vor Biopharma shares in Q4 2024, an estimated $854K.
Cowen and Company first reported a position in Vor Biopharma in Q3 2024 and held it in 1 quarter.
Cowen and Company's Vor Biopharma position peaked at $854K in Q3 2024.
50 funds tracked by Wall St. Rank held Vor Biopharma as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.